Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

Table 8 Cox regression analyses for prediction of decompensation and mortality (per 10-unit hepatic enhancement increase)

Model	Endpoint	Predictor	HR (95%CI)	P (raw)	q (FDR)
Univariate	Decompensation	HE segment VI	0.77 (0.70-0.85)	< 0.001	< 0.001
		HE segment VIII	0.81 (0.73-0.90)	< 0.001	< 0.001
		HE segment III	0.79 (0.70-0.88)	< 0.001	< 0.001
		HE caudate lobe	0.79 (0.72-0.87)	< 0.001	< 0.001
		HE global	0.77 (0.69-0.86)	< 0.001	< 0.001
	Mortality	HE segment VI	0.78 (0.68-0.90)	< 0.001	0.004
		HE segment VIII	0.86 (0.74-1.01)	0.065	0.065
		HE segment III	0.75 (0.62-0.90)	0.002	0.005
		HE caudate lobe	0.80 (0.69-0.93)	0.004	0.005
		HE global	0.79 (0.67-0.93)	0.004	0.005
Adjusted (MELD3.0, etiology, prior HCC)1	Decompensation	HE segment VI	0.87 (0.77-0.99)	0.029	0.145
		HE segment VIII	0.93 (0.83-1.05)	0.248	0.310
		HE segment III	0.91 (0.80-1.04)	0.178	0.237
		HE caudate lobe	0.92 (0.81-1.04)	0.178	0.237
		HE global	0.89 (0.79-1.02)	0.108	0.180
	Mortality	HE segment VI	0.87 (0.69-1.09)	0.227	0.695
		HE segment VIII	1.07 (0.87-1.30)	0.417	0.695
		HE segment III	0.88 (0.69-1.11)	0.284	0.710
		HE caudate lobe	0.97 (0.78-1.20)	0.733	0.733
		HE global	0.94 (0.74-1.20)	0.627	0.783

¹Multivariable models adjusted for Model for End-Stage Liver Disease 3.0, etiology, and prior hepatocellular carcinoma.

CI: Confidence interval; FDR: False discovery rate; HCC: Hepatocellular carcinoma; HE: Hepatic enhancement; HR: Hazard ratio; MELD: Model for End-Stage Liver Disease.